<DOC>
	<DOCNO>NCT01478204</DOCNO>
	<brief_summary>The purpose study evaluate sleep quality patient mild moderate Alzheimer 's disease treat anticholinesterase drug clinical practice .</brief_summary>
	<brief_title>A Study Evaluate Sleep Quality Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This epidemiological ( study health-related state event specific population ) study patient mild moderate Alzheimer 's treat previously anticholinesterase drug ( class drug act central nervous system ) maximum fifteen day . The data patient record two occasion ; first baseline visit follow-up visit 3 month . At baseline visit , patient his/her legal representative give write informed consent , participate neurologist use study questionnaire collect patient sociodemographic characteristic ( characteristic age , year education , race , sex , religion , birthplace , income , occupation , geographic location , among others ) , medical history diagnosis Alzheimer 's disease . The neurologist also record treatment Alzheimer 's disease concomitant hypnotic medication ( simultaneous use medication induce sleep ) evaluate patient use two scale : Pittsburgh Sleep Quality Index ( PSQI ) record sleep disturbance Epworth Sleepiness Scale determine level daytime sleepiness . Alzheimer treatment concomitant hypnotic medication record follow-up visit . Patient sleep quality use PSQI daytime sleepiness use Epworth scale also evaluate visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients recent diagnosis possible probable Alzheimer 's disease ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA criterion ) within maximum 60 day baseline visit . Patients mild moderate Alzheimer 's disease , define MiniMental State Exam ( MMSE ) score 11 25 . Patients whose caregiver sufficiently inform patient ' state possible live patient . Patients capable attend second clinic visit accompany person 3 month later , base clinical practice investigator . Patients and/or legal representative give sign write informed consent . Patients psychotic manifestation . Patients clinically significant sleep disorder ( sleep apnea syndrome , restless leg syndrome ) . Patients treated memantine . Patients and/or legal representative refuse give write informed consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Sleep quality</keyword>
	<keyword>Anticholinesterase drug</keyword>
</DOC>